Loading...

Brett Ley, MD

Title(s)Assistant Professor, Medicine
SchoolSchool of Medicine
vCardDownload vCard

    Collapse Biography 
    Collapse Education and Training
    University of California, Los AngelesB.S.2004Molecular, Cell, Developmental Biology
    University of California, San FranciscoM.D.2008 Medicine
    University of California, San FranciscoResidency, Internal Medicine2011Medicine
    University of California, San FranciscoChief Resident, Internal Medicine2012Medicine
    University of California, San FranciscoFellowship, Pulmonary and Critical Care2015Medicine
    University of California, San FranciscoM.A.S. in Clinical Research2016Epidemiology and Biostatistics

    Collapse Research 
    Collapse Research Activities and Funding
    Integrating clinical and molecular markers for risk prediction in idiopathic pulm
    NIH/NHLBI F32HL124895Aug 1, 2014 - Jul 31, 2017
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials
    Collapse Websites

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
    List All   |   Timeline
    1. Ley B. COUNTERPOINT: Should Molecular and Genetic Biomarkers Be Used in the Initial Evaluation of Patients With Fibrotic ILD? No. Chest. 2019 Aug; 156(2):205-208. PMID: 31395256.
      View in: PubMed
    2. Ley B. Rebuttal From Dr Ley. Chest. 2019 Aug; 156(2):209-210. PMID: 31395258.
      View in: PubMed
    3. Liu GY, Ventura IB, Achtar-Zadeh N, Elicker BM, Jones KD, Wolters PJ, Collard HR, Adegunsoye A, Strek ME, Ley B. Prevalence and Clinical Significance of Antineutrophil Cytoplasmic Antibodies in North American Patients With Idiopathic Pulmonary Fibrosis. Chest. 2019 Oct; 156(4):715-723. PMID: 31181198.
      View in: PubMed
    4. Tanizawa K, Ley B, Vittinghoff E, Elicker BM, Henry TS, Wolters PJ, Brownell R, Liu S, Collard HR, Jones KD. Significance of bronchiolocentric fibrosis in patients with histopathological usual interstitial pneumonia. Histopathology. 2019 Jun; 74(7):1088-1097. PMID: 30742318.
      View in: PubMed
    5. Erica Farrand, Eric Vittinghoff, Brett Ley, Harold Collard. 3541 The association of corticosteroid use with inpatient mortality in acute exacerbation of idiopathic pulmonary fibrosis. Journal of Clinical and Translational Science. 2019 Mar 1; 3(Suppl 1):127-128.
      View in: Publisher Site
    6. Tsui JL, Estrada OA, Deng Z, Wang KM, Law CS, Elicker BM, Jones KD, Dell SD, Gudmundsson G, Hansdottir S, Helfgott SM, Volpi S, Gattorno M, Waterfield MR, Chan AY, Chung SA, Ley B, Shum AK. Analysis of pulmonary features and treatment approaches in the COPA syndrome. ERJ Open Res. 2018 Apr; 4(2). PMID: 29977900.
      View in: PubMed
    7. Ley B, Swigris J, Day BM, Stauffer JL, Raimundo K, Chou W, Collard HR. Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2017 09 15; 196(6):756-761. PMID: 28471697.
      View in: PubMed
    8. Ley B. Clarity on Endpoints for Clinical Trials in Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc. 2017 09; 14(9):1383-1384. PMID: 28862501.
      View in: PubMed
    9. Ley B, Newton CA, Arnould I, Elicker BM, Henry TS, Vittinghoff E, Golden JA, Jones KD, Batra K, Torrealba J, Garcia CK, Wolters PJ. The MUC5B promoter polymorphism and telomere length in patients with chronic hypersensitivity pneumonitis: an observational cohort-control study. Lancet Respir Med. 2017 08; 5(8):639-647. PMID: 28648751.
      View in: PubMed
    10. Morisset J, Vittinghoff E, Elicker BM, Hu X, Le S, Ryu JH, Jones KD, Haemel A, Golden JA, Boin F, Ley B, Wolters PJ, King TE, Collard HR, Lee JS. Mortality Risk Prediction in Scleroderma-Related Interstitial Lung Disease: The SADL Model. Chest. 2017 11; 152(5):999-1007. PMID: 28629914.
      View in: PubMed
    11. Morisset J, Vittinghoff E, Lee BY, Tonelli R, Hu X, Elicker BM, Ryu JH, Jones KD, Cerri S, Manfredi A, Sebastiani M, Gross AJ, Ley B, Wolters PJ, King TE, Kim DS, Collard HR, Lee JS. The performance of the GAP model in patients with rheumatoid arthritis associated interstitial lung disease. Respir Med. 2017 06; 127:51-56. PMID: 28502419.
      View in: PubMed
    12. Ley B. A Glimpse into the Future: Automated Quantitative Computed Tomography as a Biomarker in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2017 04 01; 195(7):850-852. PMID: 28362206.
      View in: PubMed
    13. U Costabel, JJ Swigris, B Ley, J Stauffer, W Chou, K Raimundo, H Collard. Reduction in Non-Elective Respiratory-Related Hospitalizations in Patients Treated With Pirfenidone: Pooled Analyses from Three Phase 3 Trials of Pirfenidone in Idiopathic Pulmonary Fibrosis. Pneumologie. 2017 Feb 23; 71(S 01):s1-s125.
      View in: Publisher Site
    14. Brownell R, Moua T, Henry TS, Elicker BM, White D, Vittinghoff E, Jones KD, Urisman A, Aravena C, Johannson KA, Golden JA, King TE, Wolters PJ, Collard HR, Ley B. The use of pretest probability increases the value of high-resolution CT in diagnosing usual interstitial pneumonia. Thorax. 2017 May; 72(5):424-429. PMID: 28082530.
      View in: PubMed
    15. B Ley, JJ Swigris, B Day, J Stauffer, W Chou, K Raimundo, H Collard. P173 Reduction in non-elective respiratory-related hospitalizations in patients treated with pirfenidone: pooled analyses from three phase 3 trials of pirfenidone in idiopathic pulmonary fibrosis. Thorax. 2016 Dec 1; 71(Suppl 3):a177.
      View in: Publisher Site
    16. Morisset J, Johannson KA, Vittinghoff E, Aravena C, Elicker BM, Jones KD, Fell CD, Manganas H, Dubé BP, Wolters PJ, Collard HR, Ryerson CJ, Ley B. Use of Mycophenolate Mofetil or Azathioprine for the Management of Chronic Hypersensitivity Pneumonitis. Chest. 2017 03; 151(3):619-625. PMID: 27816444.
      View in: PubMed
    17. Ley B, Bradford WZ, Vittinghoff E, Weycker D, du Bois RM, Collard HR. Predictors of Mortality Poorly Predict Common Measures of Disease Progression in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2016 09 15; 194(6):711-8. PMID: 26938706.
      View in: PubMed
    18. Johannson KA, Elicker BM, Vittinghoff E, Assayag D, de Boer K, Golden JA, Jones KD, King TE, Koth LL, Lee JS, Ley B, Wolters PJ, Collard HR. A diagnostic model for chronic hypersensitivity pneumonitis. Thorax. 2016 10; 71(10):951-4. PMID: 27245779.
      View in: PubMed
    19. Ley B, Collard HR. House of Cards? Testing Fundamental Assumptions in Idiopathic Pulmonary Fibrosis Epidemiology. Am J Respir Crit Care Med. 2015 Nov 15; 192(10):1147-8. PMID: 26568236.
      View in: PubMed
    20. Johannson KA, Ley B, Collard HR. Models of disease behavior in idiopathic pulmonary fibrosis. BMC Med. 2015 Sep 24; 13:165. PMID: 26400574.
      View in: PubMed
    21. Assayag D, Vittinghoff E, Ryerson CJ, Cocconcelli E, Tonelli R, Hu X, Elicker BM, Golden JA, Jones KD, King TE, Koth LL, Lee JS, Ley B, Shum AK, Wolters PJ, Ryu JH, Collard HR. The effect of bronchodilators on forced vital capacity measurement in patients with idiopathic pulmonary fibrosis. Respir Med. 2015 Aug; 109(8):1058-62. PMID: 26140806.
      View in: PubMed
    22. Ley B, Bradford WZ, Weycker D, Vittinghoff E, du Bois RM, Collard HR. Unified baseline and longitudinal mortality prediction in idiopathic pulmonary fibrosis. Eur Respir J. 2015 May; 45(5):1374-81. PMID: 25614172.
      View in: PubMed
    23. Ley B, Brown KK, Collard HR. Molecular biomarkers in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2014 Nov 01; 307(9):L681-91. PMID: 25260757.
      View in: PubMed
    24. Ley B, Elicker BM, Hartman TE, Ryerson CJ, Vittinghoff E, Ryu JH, Lee JS, Jones KD, Richeldi L, King TE, Collard HR. Idiopathic pulmonary fibrosis: CT and risk of death. Radiology. 2014 Nov; 273(2):570-9. PMID: 24927326.
      View in: PubMed
    25. Ryerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD, Elicker BM, Wolters PJ, Koth LL, King TE, Collard HR. Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest. 2014 Apr; 145(4):723-728. PMID: 24114524.
      View in: PubMed
    26. Ley B, Collard HR. Epidemiology of idiopathic pulmonary fibrosis. Clin Epidemiol. 2013 Nov 25; 5:483-92. PMID: 24348069.
      View in: PubMed
    27. Ryerson CJ, Hartman T, Elicker BM, Ley B, Lee JS, Abbritti M, Jones KD, King TE, Ryu J, Collard HR. Clinical features and outcomes in combined pulmonary fibrosis and emphysema in idiopathic pulmonary fibrosis. Chest. 2013 Jul; 144(1):234-240. PMID: 23370641.
      View in: PubMed
    28. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, King TE, Collard HR. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann Intern Med. 2012 May 15; 156(10):684-91. PMID: 22586007.
      View in: PubMed
    29. Richeldi L, Ryerson CJ, Lee JS, Wolters PJ, Koth LL, Ley B, Elicker BM, Jones KD, King TE, Ryu JH, Collard HR. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax. 2012 May; 67(5):407-11. PMID: 22426899.
      View in: PubMed
    30. Ley B, Collard HR. Risk prediction in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2012 Jan 01; 185(1):6-7. PMID: 22210784.
      View in: PubMed
    31. Ryerson CJ, Abbritti M, Ley B, Elicker BM, Jones KD, Collard HR. Cough predicts prognosis in idiopathic pulmonary fibrosis. Respirology. 2011 Aug; 16(6):969-75. PMID: 21615619.
      View in: PubMed
    32. Ley B, Collard HR, King TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011 Feb 15; 183(4):431-40. PMID: 20935110.
      View in: PubMed